| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.51M | 48.10M | 52.35M | 44.51M | 48.52M | 27.71M |
| Gross Profit | 28.67M | 29.36M | 33.76M | 29.13M | 33.60M | 17.50M |
| EBITDA | -11.49M | -16.80M | -18.11M | -22.01M | -13.91M | -18.48M |
| Net Income | -17.26M | -23.46M | -18.71M | -23.28M | -15.20M | -11.91M |
Balance Sheet | ||||||
| Total Assets | 58.19M | 64.84M | 79.24M | 51.77M | 68.72M | 74.11M |
| Cash, Cash Equivalents and Short-Term Investments | 29.30M | 31.74M | 43.65M | 10.19M | 30.87M | 41.91M |
| Total Debt | 4.71M | 38.76M | 38.50M | 796.00K | 305.00K | 676.00K |
| Total Liabilities | 50.73M | 50.51M | 52.32M | 13.98M | 14.71M | 10.25M |
| Stockholders Equity | 7.25M | 14.21M | 26.70M | 37.58M | 53.70M | 63.72M |
Cash Flow | ||||||
| Free Cash Flow | -10.03M | -18.77M | -5.78M | -21.29M | -11.17M | -16.65M |
| Operating Cash Flow | -9.31M | -18.05M | -5.25M | -20.28M | -10.45M | -16.07M |
| Investing Cash Flow | -718.00K | -722.00K | 6.73M | -1.01M | -723.00K | -581.00K |
| Financing Cash Flow | 6.80M | 6.75M | 32.17M | 217.00K | 24.00K | -73.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $97.55M | 12.60 | 4.92% | ― | 1.43% | -20.12% | |
57 Neutral | $112.14M | -22.44 | -9.80% | ― | 15.16% | -39.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $121.40M | ― | -156.90% | ― | -5.14% | 44.86% | |
46 Neutral | $144.33M | ― | -22.91% | ― | -25.85% | 18.18% | |
45 Neutral | $94.29M | -2.72 | -123.51% | ― | 7.60% | -0.78% | |
42 Neutral | $105.68M | ― | -935.73% | ― | 38.32% | -1.31% |
Study Overview: The clinical study titled ‘Histological Evaluation of Human Skin Biopsies to Assess the Effects of Renuvion APR Treatment as an Adjunct Procedure in Facelift Surgery’ aims to evaluate the impact of the Renuvion device on skin quality. Conducted by Apyx Medical, the study focuses on measuring skin elasticity, hydration, and biological age through DNA methylation in participants undergoing lower facelift surgery.
On August 7, 2025, Apyx Medical Corporation held its annual stockholders meeting where several key proposals were voted on. The stockholders elected five directors, ratified RSM US LLP as the independent accounting firm for 2025, approved executive compensation resolutions, and amended the company’s Certificate of Incorporation. These decisions are expected to influence the company’s governance and operational strategies moving forward.
The most recent analyst rating on (APYX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Apyx Medical stock, see the APYX Stock Forecast page.
Apyx Medical’s recent earnings call painted a picture of cautious optimism, highlighting several positive developments amid some challenges. The company celebrated the successful launch of the AYON system and the expansion of Renuvion into China, both of which are expected to drive future growth. However, these advancements were tempered by a decline in overall revenue and a significant drop in the OEM segment. The sentiment expressed during the call was one of careful optimism, with a focus on the potential for growth through new product launches.
Apyx Medical Corporation is an advanced energy technology company specializing in helium plasma and radiofrequency platform technology, with products such as Renuvion and the AYON Body Contouring System in the cosmetic surgery market. The company also operates in the hospital surgical market with J-Plasma.